BENZACLIN

Compare BENZACLIN  to:
Compare
Compare

Generic Name for BENZACLIN

Clindamycin (as phosphate) 1%, benzoyl peroxide 5%; gel.

Legal Classification:

Rx

Pharmacological Class for BENZACLIN

Lincosamide antibiotic + antibacterial/keratolytic.

Manufacturer of BENZACLIN

Dermik Laboratories

Indications for BENZACLIN

Acne vulgaris.

Adult dose for BENZACLIN

Apply twice daily.

Children's dosing for BENZACLIN

Not recommended.

Contraindications for BENZACLIN

History of regional enteritis, ulcerative or antibiotic-associated colitis.

Precautions for BENZACLIN

Avoid eyes, mucous membranes, sun, UV light. Discontinue if significant diarrhea occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for BENZACLIN

Additive irritation with other topical agents. Avoid erythromycin.

Adverse Reactions for BENZACLIN

Dry skin, application site reaction, pruritus, peeling, erythema, sunburn, may bleach fabrics or hair; rare: superinfection, colitis.

How is BENZACLIN supplied?

Jar—25g
Pump—50g
BenzaClin Care Kit—(50g BenzaClin pump + 20 ampules Viscontour Serum)

Related Disease:

Acne

Related Resources

Restylane-L and Perlane-L dermal fillers approved

February 03, 2010

The FDA has approved Medicis' hyaluronic acid with lidocaine dermal fillers, Restylane-L and Perlane-L.

Juvéderm XC dermal filler approved

February 02, 2010

The FDA has approved Juvéderm XC (hyaluronic acid and lidocaine [preservative-free] injectable gel, from Allergan) dermal filler for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (eg, nasolabial folds).

BenzEFoam available for acne vulgaris

October 01, 2009

Onset Therapeutics has launched BenzEFoam (benzoyl peroxide 5.3%) emollient foam for the topical treatment of mild to moderate acne vulgaris.

BenzaClin Carekit launched for acne

August 04, 2009

Dermik Laboratories (a division of sanofi-aventis) announced the launch of the BenzaClin (clindamycin 1%-benzoyl peroxide 5% gel) Carekit for acne patients who want to add a moisturizing agent to their skin care regimen.

Accutane withdrawn from U.S. market

July 15, 2009

Roche Laboratories has announced that it has discontinued the manufacture and distribution of Accutane (isotretinoin capsules).